Bluebird bags EU conditional marketing authorisation for Zynteglo
The authorisation for the inherited blood disorder marks bluebird’s first ever drug approval.
Read More
Tag: Zynteglo
Bluebird’s Zynteglo kicks off first Amsterdam CHMP recommendations
The European Medicines Agency’s CHMP positive opinions are sparse this time around.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
